OVERVIEW OF ACTIVITY
The annual American Society of Hematology (ASH) meeting is unmatched in its importance with regard to advancements in hematologic cancer and related disorders. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results and new information lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across virtually all malignant and benign hematologic disorders. As online access to posters and plenary presentations is not currently available, a need exists for additional resources to distill the information presented at the ASH annual meeting for those clinicians unable to attend but desiring to remain up to date on the new data released there. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists, hematologists and hematology-oncology fellows in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care.
LEARNING OBJECTIVES
Please see individual web programs for CME program-specific information.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Please see individual web programs for CME program-specific information.
HOW TO USE THIS CME ACTIVITY
Please see individual web programs for CME program-specific information.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Please see individual web programs for CME program-specific information.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Allos Therapeutics, Celgene Corporation, Genentech BioOncology/Biogen Idec, Incyte Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Sanofi and Seattle Genetics.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: January/February/March/April 2012
Expiration date: January/February/March/April 2013
Overview This 9-part web program is part of an email series designed for dedicated but frenzied oncology professionals attempting to keep up with an exploding clinical research database. Subscribers to this program receive emails that include links to slides from important data sets presented at ASH 2011 along with brief comments from clinical investigators about the significance of these results. Current Issue 
Read Dr Love’s original email (from April 27, 2012)
Therapeutic Measures to Improve Clinical Outcomes for Patients with Indolent Non-Hodgkin Lymphoma, Including Follicular Lymphoma and Chronic Lymphocytic Leukemia
Program Description: Study reports on the safety and efficacy of mono- and combination therapies and prognostic measures with the potential for improving treatment outcomes for patients with newly diagnosed, relapsed or refractory follicular lymphoma, chronic lymphocytic leukemia and other indolent non-Hodgkin lymphomas.
Full Abstracts:
Lenalidomide/Rituximab in CLL
Badoux XC et al. Final analysis of a Phase 2 study of lenalidomide and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Proc ASH 2011; Abstract 980.
James DF et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia (CLL): A multicenter study of the CLL research consortium. Proc ASH 2011; Abstract 291.
Egle A et al. A combination of fludarabine/rituximab with escalating doses of lenalidomide in previously untreated chronic lymphocytic leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II study, clinical and exploratory analyses of induction results. Proc ASH 2011; Abstract 292.
Immunochemotherapy with Alemtuzumab and FC in High-Risk CLL
Geisler CH et al. Immunochemotherapy with low-dose subcutaneous alemtuzumab (A) plus oral fludarabine and cyclophosphamide (FC) is safe and induces more and deeper complete remissions in untreated patients with high-risk chronic lymphocytic leukemia (CLL) than chemotherapy with FC alone. An early analysis of the randomized Phase-III HOVON68 CLL trial. Proc ASH 2011; Abstract 290.
Obinutuzumab (GA101) in Relapsed/Refractory Non-Hodgkin Lymphoma
Salles GA et al. Efficacy and safety of obinutuzumab (GA101) monotherapy in relapsed/refractory indolent non-Hodgkin’s lymphoma: Results from a Phase I/II study (BO20999). Proc ASH 2011; Abstract 268.
Sehn LH et al. Randomized Phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20+ indolent B-cell non‑Hodgkin lymphoma: Preliminary analysis of the GAUSS study. Proc ASH 2011; Abstract 269.
Radford J et al. Obinutuzumab (GA101) in combination with FC or CHOP in patients with relapsed or refractory follicular lymphoma: Final results of the Phase I GAUDI study (BO21000). Proc ASH 2011; Abstract 270.
Radioimmunotherapy for FL
Press OW et al. A Phase III randomized intergroup trial (SWOG S0016) of CHOP chemotherapy plus rituximab vs CHOP chemotherapy plus iodine-131-tositumomab for the treatment of newly diagnosed follicular non-Hodgkin’s lymphoma. Proc ASH 2011; Abstract 98.
Illidge TM et al. Fractionated 90Y ibritumomab tiuxetan (ZevalinTM) radioimmunotherapy as an initial therapy of follicular lymphoma — First results from a Phase II study in patients requiring treatment according to GELF/BNLI criteria. Proc ASH 2011; Abstract 102.
Prognostic Impact of FDG-PET in FL
Dupuis J et al. Significant prognostic impact of [18F]fluorodeoxyglucose-PET scan performed during and at the end of treatment with R-CHOP in high-tumor mass follicular lymphoma patients: A GELA-GOELAMS study. Proc ASH 2011; Abstract 877.
Bortezomib/Rituximab versus Rituximab for Relapsed/Refractory FL
Coiffier B et al. Identification of patient subgroups demonstrating longer progression-free survival (PFS) benefit with bortezomib-rituximab versus rituximab in patients with relapsed or refractory follicular lymphoma (FL): Biomarker analyses of the Phase 3 LYM3001 study. Proc ASH 2011; Abstract 265.
Issue 8 — April 11, 2012
Read Dr Love’s original email (from April 11, 2012)
Therapy with Targeted Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia
Program Description: Study reports on the safety and efficacy of multitargeting tyrosine kinases in the treatment of newly diagnosed, relapsed or refractory chronic myeloid leukemia in chronic, accelerated or blast phase.
Full Abstracts:
Efficacy of Nilotinib in CML-CP: Results from the ENEST Studies
Saglio G et al. Nilotinib versus imatinib in patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 36-month (mo) follow-up. Proc ASH 2011; Abstract 452.
Hughes TP et al. Complete molecular response (CMR) rate with nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) without CMR after ≥ 2 years on imatinib: Preliminary results from the randomized ENESTcmr trial of nilotinib 400 mg twice daily (bid) vs imatinib. Proc ASH 2011; Abstract 606.
Hochhaus A et al. Results from the ENESTnd extension study: Efficacy and safety of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP), treated with nilotinib 400 mg twice daily (bid) after suboptimal response (SoR) or treatment failure (TF) to imatinib 400 mg once daily (qd) or nilotinib 300 mg bid. Proc ASH 2011; Abstract 114.
Novel Agents Bosutinib and Ponatinib in CML and ALL: Results from the BELA and PACE Trials
Cortes JE et al. Initial findings from the PACE trial: A pivotal Phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. Proc ASH 2011; Abstract 109.
Cortes JE et al. Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia — BELA trial: 24-month follow-up. Proc ASH 2011; Abstract 455.
Prediction of Risk of Disease Progression and Death in CML After Imatinib Treatment
Hanfstein B et al. Molecular and cytogenetic response after 3 months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients — A follow-up analysis of the German CML study IV. Proc ASH 2011; Abstract 783.
Discontinuation of Imatinib, Dasatinib or Nilotinib in CML
Mahon FX et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: Update results of the STIM study. Proc ASH 2011; Abstract 603.
Rea D et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia (CML) patients (pts) with stable undetectable bcr-abl transcripts: Results from the French CML group (FILMC). Proc ASH 2011; Abstract 604.
Issue 7 — March 26, 2012
Read Dr Love’s original email (from March 26, 2012)
Induction and Maintenance Therapies for Elderly Patients with Multiple Myeloma
Program Description: Study reports on the safety and efficacy of lenalidomide- and bortezomib–based induction and maintenance therapies for older patients with multiple myeloma.
Full Abstracts:
Lenalidomide Maintenance After Lenalidomide/Melphalan/Prednisone for Elderly Patients with Newly Diagnosed MM
Palumbo A et al. A Phase 3 study evaluating the efficacy and safety of lenalidomide (len) combined with melphalan and prednisone followed by continuous lenalidomide maintenance (MPR-R) in patients (pts) ≥ 65 years (yrs) with newly diagnosed multiple myeloma (NDMM): Updated results for pts aged 65-75 yrs enrolled in MM-015. Proc ASH 2011; Abstract 475.
Lenalidomide for Newly Diagnosed MM and the Incidence of Second Primary Cancer
Palumbo A et al. Second primary malignancies in newly diagnosed multiple myeloma patients treated with lenalidomide: Analysis of pooled data in 2459 patients. Proc ASH 2011; Abstract 996.
UPFRONT Study of Bortezomib-Based Combinations for Elderly Patients with Newly Diagnosed MM
Niesvizky R et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: Results from all randomized patients in the community-based, phase 3b UPFRONT study. Proc ASH 2011; Abstract 478.
Final Results of the Phase III VISTA Trial: VMP versus MP for Previously Untreated MM
San Miguel JF et al. Continued overall survival benefit after 5 years’ follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: Final results of the phase 3 VISTA trial. Proc ASH 2011; Abstract 476.
Bortezomib with Thalidomide or with Prednisone as Maintenance Therapy for Elderly Patients with MM: The GEM20005MAS65 Trial
Mateos MV et al. Maintenance therapy with bortezomib plus thalidomide (VT) or bortezomib plus prednisone (VP) in elderly myeloma patients included in the GEM2005MAS65 Spanish randomized trial. Proc ASH 2011; Abstract 477.
Issue 6 — March 15, 2012
Read Dr Love’s original email (from March 15, 2012)
Investigation of Current and Novel Therapeutic Approaches for Aggressive Non-Hodgkin and Peripheral and Cutaneous T-Cell Lymphomas
Program Description: A summary of the results from key Phase II, III and IV trials in diffuse large B-cell, mantle-cell, peripheral T-cell and cutaneous T-cell lymphomas.
Full Abstracts:
Phase II Trial of Lenalidomide/Rituximab +/- Dexamethasone in Relapsed/Refractory B-Cell Lymphomas or MCL Resistant to Rituximab
Ahmadi T et al. Phase II trial of lenalidomide - rituximab +/- dexamethasone in relapsed or refractory indolent B-cell or mantle cell lymphomas resistant to rituximab. Proc ASH 2011; Abstract 266.
Single-Agent PCI-32765 in Previously Treated MCL and Rituximab/Fludarabine/Cyclophosphamide in Newly Diagnosed MCL
Wang L et al. The Bruton’s tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): Preliminary results of a Phase II trial. Proc ASH 2011; Abstract 442.
Rule S et al. The addition of rituximab to fludarabine and cyclophosphamide (FC) improves overall survival in newly diagnosed mantle cell lymphoma (MCL): Results of the randomised UK National Cancer Research Institute (NCRI) trial. Proc ASH 2011; Abstract 440.
Chemotherapy and Rituximab for NHL: Results from the Dose-Adjusted EPOCH Study
Purroy N et al. Dose-adjusted EPOCH plus rituximab in untreated patients with poor prognosis large B-cell, with analysis of germinal center and activated B-cell biomarkers. A Phase IV study conducted by the Spanish PETHEMA group. Proc ASH 2011; Abstract 593.
Rituximab/BEAM versus 131 Iodine-Tositumomab/BEAM prior to SCT for Relapsed DLBCL
Vose JM et al. Randomized Phase III trial of 131-iodine-tositumomab/carmustine, etoposide, cytarabine, melphalan (BEAM) vs rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): No difference in progression-free (PFS) or overall survival (OS). Proc ASH 2011; Abstract 661.
Phase II Trials in T-Cell Lymphoma: Romidepsin and Pegylated Liposomal Doxorubicin/Bexarotene
Coiffier B et al. Analysis of patients with common peripheral T-cell lymphoma subtypes from a Phase 2 study of romidepsin in relapsed or refractory peripheral T-cell lymphoma. Proc ASH 2011; Abstract 591.
Straus DJ et al. Final results of Phase II trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene (Bex) in advanced cutaneous T-cell lymphoma (CTCL). Proc ASH 2011; Abstract 882.
Issue 5 — March 5, 2012
Read Dr Love’s original email (from March 5, 2012)
Therapeutic Approaches, Risk Assessment and Incidence of Venous Thrombosis
Program Description: A summary of the results from key trials on the prophylactic treatment, risk assessment and incidence of venous thrombosis, including deep vein thrombosis and venous thromboembolism.
Full Abstracts:
SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism
Agnelli G et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366(7):601-9. Abstract
George DJ et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: Benefit-risk assessment by VTE risk in SAVE-ONCO. Proc ASH 2011; Abstract 206.
Incidence of Venous Thromboembolism in Patients with Cancer
Khorana AA et al. Higher incidence of venous thromboembolism in the outpatient versus the inpatient setting among US cancer patients. Proc ASH 2011; Abstract 674.
Risk Assessment Model for Venous Thrombosis
Zakai N et al. Development and testing of a risk assessment model for venous thrombosis in medical inpatients: The medical inpatients and thrombosis (MITH) study score. Proc ASH 2011; Abstract 173.
CaVenT Study of Additional Catheter-Directed Thrombolysis versus Standard Treatment for Acute Iliofemoral Deep Vein Thrombosis
Enden T et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): A randomised controlled trial. Lancet 2012;379(9810):31-8. Abstract
Enden TR et al. Improved functional outcome after additional catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis: Results of a randomized controlled clinical trial (the CaVenT study). Proc ASH 2011; Abstract LBA-1.
Dabigatran versus Warfarin for Acute Venous Thromboembolism
Schulman S et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). Proc ASH 2011; Abstract 205.
Issue 4 — February 23, 2012
Read Dr Love’s original email (from February 23, 2012)
Investigation of JAK1/JAK2 Inhibitors and Other Novel Therapeutic Agents for Patients with Myelofibrosis
Program Description: A summary of the preliminary and updated results of studies of JAK1/2 inhibitors and pan-deacetylase inhibitors for primary, postpolycythemia vera and postessential thrombocythemia myelofibrosis and a report on the efficacy and safety data with pegylated interferon alpha-2a (peg-IFN a-2a) for polycythemia vera.
Full Abstracts:
COMFORT-I Phase III Trial of the Benefit of Ruxolitinib versus Placebo on Spleen Volume Reduction and Symptom Improvement
Verstovsek S et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: Results from COMFORT-I. Proc ASH 2011; Abstract 278.
COMFORT-II Phase III Trial of Splenomegaly Reduction with Ruxolitinib in Myelofibrosis
Harrison CN et al. Ruxolitinib provides reductions in splenomegaly across subgroups: An analysis of spleen response in the COMFORT-II study. Proc ASH 2011; Abstract 279.
Survival Advantage of Ruxolitinib in Advanced Myelofibrosis
Verstovsek S et al. Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib (INCB018424) to those of a historical control group: Survival advantage of ruxolitinib therapy. Proc ASH 2011; Abstract 793.
Novel JAK2 Inhibitors Pacritinib and SAR302503 for Myelofibrosis
Komrokji RS et al. Results of a Phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Proc ASH 2011; Abstract 282.
Pardanani A et al. SAR302503: Interim safety, efficacy and long-term impact on JAK2 V617F allele burden in a Phase I/II study in patients with myelofibrosis. Proc ASH 2011; Abstract 3838.
Phase II Results with Pegylated Interferon Alpha-2a Therapy in Polycythemia Vera
Turlure P et al. Complete hematological, molecular and histological remissions without cytoreductive treatment lasting after pegylated-interferon α-2a (peg-IFNα-2a) therapy in polycythemia vera (PV): Long term results of a Phase 2 trial. Proc ASH 2011;Abstract 280.
Prolonged Low-Dose Pan-Deacetylase Inhibitor Panobinostat and Pomalidomide in Myelofibrosis
Mascarenhas J et al. Prolonged low dose therapy with a pan-deacetylase inhibitor, panobinostat (LBH589), in patients with myelofibrosis. Proc ASH 2011; Abstract 794.
Shastri A et al. Phase II study of low-dose pomalidomide in patients with myelofibrosis and significant anemia (hemoglobin <10 g/dL). Proc ASH 2011; Abstract 1757.
Begna K et al. Pomalidomide therapy for myelofibrosis: Analysis of results from three consecutive clinical trials. Proc ASH 2011; Abstract 1759.
Issue 3 — February 9, 2012
Read Dr Love’s original email (from February 9, 2012)
Investigation of Novel Agents for Patients with Newly Diagnosed and Relapsed or Refractory Multiple Myeloma
Program Description: A summary of the preliminary and updated results of studies on therapeutic novel agents for the treatment of newly diagnosed and relapsed or refractory multiple myeloma.
Full Abstracts:
Carfilzomib with Lenalidomide and Low-Dose Dexamethasone or Single-Agent Carfilzomib for Patients with Multiple Myeloma
Jakubowiak AJ et al. Final results of a frontline Phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM). Proc ASH 2011; Abstract 631.
Vij R et al. Final results from the bortezomib-naïve group of PX-171-004, a Phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory MM. Proc ASH 2011; Abstract 813.
Investigational Agent MLN9708 for Patients with Relapsed/Refractory Multiple Myeloma
Richardson PG et al. Investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): Results from the expansion cohorts of a Phase 1 dose-escalation study. Proc ASH 2011; Abstract 301.
Kumar S et al. Weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: Results from a phase 1 dose-escalation study. Proc ASH 2011;Abstract 816.
Berdeja JG et al. Phase 1/2 study of oral MLN9708, a novel, investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). Proc ASH 2011; Abstract 479.
Pomalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma
Richardson PG et al. Randomized, open label Phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): Phase 2 results. Proc ASH 2011; Abstract 634.
Leleu X et al. High response rates to pomalidomide and dexamethasone in patients with refractory myeloma, final analysis of IFM 2009-02. Proc ASH 2011; Abstract 812.
Phase II Trial of Elotuzumab with Lenalidomide and Low-Dose Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma
Lonial S et al. A Phase 2 study of elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. Proc ASH 2011; Abstract 303.
Deacetylase Inhibitors Vorinostat or Panobinostat for Relapsed/Refractory Multiple Myeloma
Siegel DS et al. Vantage 095: Vorinostat in combination with bortezomib in salvage multiple myeloma patients: Final study results of a global Phase 2b trial. Proc ASH 2011; Abstract 480.
Richardson PG et al. Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in relapsed and bortezomib-refractory multiple myeloma (PANORAMA 2). Proc ASH 2011; Abstract 814.
San-Miguel JF et al. Update on a Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma: PANORAMA 1. Proc ASH 2011; Abstract 3976.
Issue 2 — January 31, 2012
Read Dr Love’s original email (from January 31, 2012)
Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (sALCL) or Relapsed/Refractory Advanced-Stage Hodgkin Lymphoma
Program Description: A summary of the results of Phase I, Phase II and retrospective studies and a study on the extended use of brentuximab vedotin for patients with relapsed or refractory anaplastic large cell lymphoma or advanced-stage Hodgkin lymphoma.
Full Abstracts:
Phase II Study Update of Brentuximab Vedotin in Patients with Relapsed/Refractory Systemic ALCL
Advani RH et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: A Phase 2 study update. Proc ASH 2011; Abstract 443.
Treatment with Brentuximab Vedotin Prior to Reduced Intensity Allogeneic HCT in Relapsed/Refractory HL
Chen RW et al. Brentuximab vedotin (SGN-35) enables successful reduced intensity allogeneic hematopoietic cell transplantation in relapsed/refractory Hodgkin lymphoma. Proc ASH 2011; Abstract 664.
Allogeneic Transplant After Brentuximab Vedotin in Patients with Relapsed/Refractory CD30+ Lymphomas
Illidge T et al. Allogeneic transplant following brentuximab vedotin treatment in patients with relapsed or refractory CD30+ lymphomas. Proc ASH 2011; Abstract 3091.
Prolonged Treatment with Brentuximab Vedotin in Patients with Relapsed/Refractory HL or Systemic ALCL
Forero-Torres A et al. Prolonged treatment with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). Proc ASH 2011; Abstract 3711.
Efficacy and Safety of Brentuximab Vedotin with ABVD or AVD in Newly Diagnosed Advanced HL
Younes A et al. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. Proc ASH 2011; Abstract 955.
Issue 1 — January 24, 2012
Read Dr Love’s original email (from January 24, 2012)
RESORT Trial and Maintenance Rituximab in Non-Hodgkin Lymphoma
Program Description: A summary of the efficacy and safety results from several Phase II and III trials examining rituximab maintenance in patients with follicular lymphoma, mantle-cell lymphoma or chronic lymphocytic leukemia.
Full Abstracts:
RESORT Trial Evaluating Different Dosing Strategies for Low Tumor Burden FL
Kahl BS et al. Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized Phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Proc ASH 2011; Abstract LBA-6.
Rituximab Maintenance versus Observation After Response to R-FND and R Consolidation in Elderly Patients with Advanced FL
Vitolo U et al. Brief chemoimmunotherapy R-FND with rituximab consolidation followed by randomization between rituximab maintenance vs observation as first line treatment in elderly patients with advanced follicular lymphoma (FL): Final results of a prospective randomized trial by Italian Lymphoma Foundation (FIL). Proc ASH 2011; Abstract 777.
R-CHOP versus R-FC Followed by Rituximab versus IFN Maintenance in Elderly Patients with MCL
Kluin-Nelemans JC et al. R-CHOP versus R-FC followed by maintenance with rituximab versus interferon-alfa: Outcome of the first randomized trial for elderly patients with mantle cell lymphoma. Proc ASH 2011; Abstract 439.
GELCC Phase II Trial of Rituximab Maintenance in Patients with CLL After Up-Front R-FCM
Bosch F et al. Rituximab maintenance in patients with chronic lymphocytic leukemia (CLL) after upfront treatment with rituximab plus fludarabine, cyclophosphamide, and mitoxantrone (R-FCM): Final results of a multicenter Phase II trial on behalf of the Spanish CLL Study Group (GELLC). Proc ASH 2011; Abstract 293.
Phase II Study of R-FND Followed by Radioimmunotherapy and R Maintenance for High-Risk FL
Fowler NH et al. Phase II study with R-FND followed by 90-Y ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance for untreated high-risk follicular lymphoma. Proc ASH 2011; Abstract 99.
|
